Virus‐triggered secondary hemophagocytic lymphohistiocytosis

Primary (familial/hereditary) and secondary (non‐familial/hereditary) hemophagocytic lymphohistiocytosis (HLH) are hyperinflammatory and hypercytokinemic syndromes. Secondary HLH includes infection‐ (eg viral/bacterial/fungal/parasitic) and non–infection‐ (eg collagen disease or malignancy) related diseases. Viral HLH is the major type among all age groups. Secondary viral HLH and primary HLH must be differentiated carefully because primary HLH can be associated with viral infection(s), and the outcome is dismal without a timely diagnosis and hematopoietic stem cell transplantation (HSCT). Epstein‐Barr virus (EBV)‐related HLH (EBV‐HLH) is the most common type of viral HLH in childhood. For non–EBV‐HLH, appropriate treatment of viral infection, followed by immunomodulatory agent(s) such as corticosteroids, intravenous immunoglobulin or cyclosporine A, is usually successful; however, recent SARS‐CoV‐2‐related HLH may become life‐threatening. EBV‐HLH may occur heterogeneously associated with the primary infection, with chronic active EBV infection or with underlying primary HLH. Although immunomodulatory agent(s) are effective in the majority of EBV‐HLH cases, management differs from that of non–EBV‐HLH because severe and refractory cases may require etoposide‐containing HLH‐1994/2004 regimens or other experimental agents. The novel agent, emapalumab (an anti–IFN‐γ monoclonal antibody) can be used to treat EBV‐HLH cases to avoid the risk of secondary malignancy due to etoposide. Finally, HSCT is required for refractory EBV‐HLH cases and can also be curative in some other cases.